The deal – financials of which have not been divulged – adds PDC’s range of sterile fill and finish products to Meissner’s filtration, single-use fluid handling and unit processing portfolio.
“PDC brings innovative technology and equipment to Meissner which augments our current capacity in two primary areas, automated filling systems and unique tube sealing equipment,” a Meissner spokesperson told this piublication.
“Both are hugely synergistic with our existing portfolio as well as our organizational trajectory whereby we are widening the breadth of complete unit processing operations we offer to the marketplace.”
The firm will be wholly integrated into Meissner, the spokesperson added, though this will be done over a period of time to ensure a “truly seamless” experience for the two firms’ client base.
“We expect this acquisition to integrate very well with our existing pharma business but more important than how it supports our business, is what these additional process solutions offer our clients and how it supports their operations.”
Growing biopharma demand
We were also told the expansion of Meissner’s processing business has been driven by a number of drivers within the pharma industry.
“Risk mitigation is always a primary concern, however there are also some additional market dynamics that bear consideration.”
These include processing smaller fluid volumes as productivity per liter increases at the same time as targeted populations bases are in general becoming smaller, leading to demand for products which can streamline the aseptic handling of closed system aliquots, we were told.
Other factors driving demand for tools which enhance productivity include increased competition in the marketplace from biosimilars, the firm added.